by Combat Cancer | Aug 16, 2025 | News
Non–muscle–invasive bladder cancer (NMIBC) presents a significant therapeutic challenge. Nearly 70% of NMIBC cases recur, and a considerable subset progress to muscle invasion, requiring radical cystectomy – a procedure which many patients either refuse or...
by Combat Cancer | Aug 9, 2025 | News
Intravesical Bacillus Calmette‑Guérin (BCG) following transurethral resection of bladder tumour (TURBT) remains the primary treatment strategy for intermediate‑ and high‑risk non‑muscle‑invasive bladder cancer (NMIBC). Nevertheless, around four in ten patients...
by Combat Cancer | Aug 1, 2025 | News
In pancreatic ductal adenocarcinoma (PDAC), the most common and deadliest form of pancreatic cancer, pancreatic cancer cells drastically reprogram nearby normal fibroblasts – cells that normally maintain tissue structure and repair – to become...
Recent Comments